vandetanib
Also known as Caprelsa®, CH 331, ZD 6474, ZD-6474, ZD6474, N-(4-Bromo-2-fluorophenyl)-6-methoxy-7-((1-methyl-4-piperidinyl)methoxy)-4-quinazolinamine, N-(4-Bromo-2-fluorophenyl)-6-methoxy-7-((1-methylpiperidin-4-yl)methoxy)quinazolin-4-amine
Vandetanib, sold under the brand name Caprelsa, is an anti-cancer medication that is used for the treatment of certain tumors of the thyroid gland. It acts as a kinase inhibitor of a number of cell receptors, mainly the vascular endothelial growth factor receptor, the epidermal growth factor receptor, and the RET-tyrosine kinase. The drug was developed by AstraZeneca who sold the rights to Sanofi in 2015.
Chemical data
- Formula
- C22H24BrFN4O2
- Molecular weight
- 475.4 g/mol
- IUPAC name
- N-(4-bromo-2-fluorophenyl)-6-methoxy-7-[(1-methylpiperidin-4-yl)methoxy]quinazolin-4-amine
via PubChem
Drug data · ChEMBL
- Max clinical phase
- Approved
- Molecule type
- Small molecule
- First approval
- 2011
- Admin. routes
- oral
- Indications
- mesothelioma, pancreatic carcinoma, thyroid carcinoma, non-small cell lung carcinoma
via ChEMBL · EBI
Research
1,152 papers~5 min read
Article
8 sectionsContents
- Medical use
- Contraindications
- Adverse effects
- Interactions
- Pharmacology
- History
- Research
- References
Vandetanib, sold under the brand name Caprelsa, is an anti-cancer medication that is used for the treatment of certain tumors of the thyroid gland. It acts as a kinase inhibitor of a number of cell receptors, mainly the vascular endothelial growth factor receptor, the epidermal growth factor receptor, and the RET-tyrosine kinase. The drug was developed by AstraZeneca who sold the rights to Sanofi in 2015.
==Medical use== Vandetanib is indicated for the treatment of symptomatic or progressive medullary thyroid cancer in people with unresectable locally advanced or metastatic disease. Vandetanib is used to treat medullary thyroid cancer in adults who are ineligible for surgery.